A Needham analyst cut Alphatec Holdings’ price target from $25 to $14, indicating 95.5% upside potential from current levels. The reduction reflects a cautious near-term outlook on the medical technology company’s growth prospects.

In the first quarter Alphatec reported break-even EPS compared with an estimated $0.01 loss, marking significant improvement from a $0.23 per share loss a year earlier. Revenues reached $192.11 million but fell short of analyst forecasts, highlighting challenges in sales growth.

Alphatec stock slid 29.86% in response to the revenue shortfall and earnings update. The decline accelerated after a fund sold 1.2 million shares, raising concerns over shareholder confidence and potential further volatility.